Showing results (51-60 of 178) with videos related to

Sort By:
Pageof 18
Oncotarget|September 1, 2018
A Phase Ib, open-label, dose-finding study of alpelisib in combination with paclitaxel in patients with advanced solid tumorsJordi Rodon, Giuseppe Curigliano, Jean-Pierre Delord, et al.
Pharmaceuticals (Basel, Switzerland)|May 27, 2023
RadioLigand Therapy with [<sup>177</sup>Lu]Lu-PSMA-617 for Salivary Gland Cancers: Literature Review and First Compassionate Use in FranceMarie Terroir, Chloé Lamesa, Mehdi Krim, et al.
Bulletin Du Cancer|October 5, 2012
[Compensable occupational disease and cancer: how to improve the recognition rate? "Cursus Laboris" Project in Midi-Pyrenees: feasibility study]Marie-Eve Rougé-Bugat, Fabrice Hérin, Sylvie Julien, et al.
British Journal of Clinical Pharmacology|November 29, 2013
How to manage intravenous vinflunine in cancer patients with renal impairment: results of a pharmacokinetic and tolerability phase I studyNicolas Isambert, Jean Pierre Delord, Jean Marc Tourani, et al.
International Journal of Cancer|November 24, 2020
Improving patient selection for immuno-oncology phase 1 trials: External validation of six prognostic scores in a French Cancer CenterGhassan Al Darazi, Elodie Martin, Jean-Pierre Delord, et al.
Investigational New Drugs|December 15, 2018
Phase I dose-escalation study of F14512, a polyamine-vectorized topoisomerase II inhibitor, in patients with platinum-refractory or resistant ovarian cancerAlexandra Leary, Christophe Le Tourneau, Andrea Varga, et al.
Investigational New Drugs|May 30, 2018
Phase I dose-escalation trial of afatinib, an irreversible ErbB family blocker, in combination with gemcitabine or docetaxel in patients with relapsed or refractory solid tumorsSandrine Hiret, Nicolas Isambert, Carlos Gomez-Roca, et al.
European Journal of Cancer (Oxford, England : 1990)|September 18, 2018
Addressing heterogeneity in the design of phase II clinical trials in geriatric oncologyBastien Cabarrou, Patrick Sfumato, Loïc Mourey, et al.
Investigational New Drugs|September 25, 2014
A phase I open-label study of the safety, tolerability, and pharmacokinetics of pazopanib in combination with irinotecan and cetuximab for relapsed or refractory metastatic colorectal cancerJaafar Bennouna, Marion Deslandres, Helene Senellart, et al.
European Urology|February 27, 2023
Assessing Long-term Treatment Benefits Using Complementary Statistical Approaches: An In Silico Analysis of the Phase III Keynote-045 and Checkmate-214 Immune Checkpoint Inhibitor TrialsAna Cavillon, Damien Pouessel, Nadine Houédé, et al.
Pageof 18